Shanghai - Delayed Quote • CNY Shanghai Junshi Biosciences Co., Ltd. (688180.SS) Follow Add holdings 28.84 +0.41 +(1.44%) At close: May 16 at 3:00:01 PM GMT+8 Comparisons Indicators Technicals Corporate Events Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for 688180.SS 1D 5D 1M 3M 6M YTD 1Y 5Y All Date Range 1 min Recent News: 688180.SS View More All News Press Releases SEC Filings BioDlink Congratulates Junshi Biosciences on IND Approval of JS212, a Bispecific ADC Therapeutic Candidate Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates Junshi Biosciences Announces Toripalimab’s Approval in Singapore Junshi Biosciences Announces Approval of sNDA for Toripalimab in Combination with Bevacizumab for 1st-line Treatment of Advanced Hepatocellular Carcinoma Junshi Biosciences Announces Commercialization Partnership with LEO Pharma for Toripalimab in Europe Junshi Biosciences Announces Toripalimab’s Approval in Australia Junshi Biosciences Announces UK MHRA Approval for Marketing of Toripalimab Junshi Biosciences Announces Toripalimab Obtained Approval for Marketing in India and China’s Hong Kong SAR Junshi Biosciences Announces European Commission Approval for Marketing of Toripalimab Junshi Biosciences Announces 2024 Interim Financial Results and Provides Corporate Updates